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BACKGROUND: To evaluate the impact of treatment on health states that affect patients’ quality of life in advanced follicular lymphoma.
METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data
from a phase III clinical trial (Marcus et al, 2008).
RESULTS: Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in
TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with
cyclophosphamide, vincristine, and prednisone (CVP)-treated patients.
CONCLUSION: Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months
in quality-adjusted survival compared with CVP.
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Follicular lymphoma (FL) is the most common form of
non-Hodgkin’s lymphoma (NHL), accounting for about 70% of
indolent lymphomas and 20–25% of all cases of NHL (NHL
classification project, 1997). Follicular lymphoma is characterised
by slow disease progression and exhibits repeated chemotherapy-
induced remissions followed by relapses, with times of remission
and a median survival of 6–10 years (Horning, 1993), depending
on the stage of disease and other prognostic variables at diagnosis.
An open-label, randomised, multi-centre phase III trial investi-
gated the clinical outcomes of previously untreated FL patients
who received eight cycles of cyclophosphamide, vincristine, and
prednisone (CVP) vs eight cycles of CVP plus rituximab (R-CVP)
therapy (Marcus et al, 2005). The recently published 53-month
median follow-up data showed that R-CVP-treated patients
experienced clinically significant improvements in time to treat-
ment failure and overall survival (OS), without an increase in
clinically significant toxicity (Marcus et al, 2008). Although
treatment goals for FL include freedom from symptomatic disease
and toxicity-related impairment of quality of life (QoL), no QoL
parameters were collected in this trial.
It is reasonable to assume that patients with no disease
symptoms or treatment toxicity will have better health-related
quality of life (HR-QoL) than those exhibiting disease symptoms
and toxicity. Our objective was to conduct a quality-adjusted time
without symptoms of disease or toxicity of treatment (Q-TWiST)
analysis on the 53-month follow-up data from the phase III trial
(Marcus et al, 2008). The Q-TWiST method was initially used
to evaluate adjuvant therapies for breast cancer (Fairclough et al,
1999), and has since been applied to trials of interferon in
advanced FL (Cole et al, 1998) and multiple myeloma (Zee et al,
1998).
MATERIALS AND METHODS
Patient population and treatment comparators
The design and main results of the phase III randomised, con-
trolled clinical trial have been reported elsewhere (Marcus et al,
2005, 2008).
Analyses were conducted on all patients who received at least
one administration of study medication. Patients were randomly
assigned to R-CVP (n¼162) or CVP alone (n¼159). Patients
treated with CVP alone received a combination of cyclo-
phosphamide 750mgm
 2 i.v. on day 1; vincristine 1.4mgm
 2,
up to a maximal dose of 2mg i.v. on day 1; and prednisone
40mgm
 2 p.o. on days 1–5. Patients treated with R-CVP also
received rituximab 375mgm
 2 i.v. on day 1 of each treatment
cycle (length 21 days). Patients were treated for a maximum of
eight cycles.
Q-TWiST analysis
The Q-TWiST analysis was performed on the 321 patients
and consisted of three steps (Staquet et al, 1998; Fayers and
Machin, 2000).
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sStep 1: Definition of clinical health states The clinical health
states considered relevant to treatment decision-making in
patients with FL were as follows: TOX – the time period with
treatment-related adverse events; REL – the time period with
disease relapse (progression), ending with death or censoring; and
TWiST – the time period during which patients experienced no
disease symptoms or treatment toxicities, thus reflecting the best
possible patient HR-QoL in this clinical setting.
This Q-TWiST analysis was performed using all investigator-
determined treatment-related adverse events occurring from the
start of treatment until 28 days beyond the last protocol-defined
dose or progression. Although there was a higher incidence of
grade 3–4 neutropenia during treatment with R-CVP, this did not
translate into a higher infection rate (Marcus et al, 2005, 2008).
Step 2: Estimation of health state duration Mean duration of OS
partitioned into health states TOX, TWiST, and REL was estimated
from the phase III trial data (Marcus et al, 2008). Owing to the
shorter follow-up in the CVP arm, the event data were truncated to
67 months, the longest follow-up in the shortest progression-free
curve of the comparator, to exclude follow-up time bias in favour
of R-CVP. The mean duration of toxicity was calculated without
restriction, whereas the mean time spent in REL and TWiST was
restricted to the clinical follow-up period. These estimates are
represented by the area between the partitioned curves (Figure 1).
Step 3: Estimation of Q-TWiST A quality-adjusted survival model
was developed with the use of utility coefficients for uTOX, uTWiST,
and uREL to reflect the impact on the patient’s HR-QoL. The utility
coefficients are measured on a scale from 0 to 1, where 0 represents
death and 1 represents the best possible patient QoL. Quality-
adjusted time without disease symptoms or toxicities of treatment,
defined as the weighted sum of time spent in each disease state is
calculated as:
Q-TWiST ¼ðuTOX TOXiÞþð uREL RELiÞ
þð uTWiST TWiSTiÞ; i ¼f R-CVP; CVPg
The utility weight of 0.618 (s.e., 0.056) used for REL was obtained
from the UK study in 222 patients with FL (Pettengell et al, 2008).
The base case Q-TWiST analysis assumed a TWiST utility of 1.0
and a utility of 0.618 for REL and TOX.
Statistical analysis
Point estimates of mean differences in OS, progression-free
survival (PFS), disease relapse (REL¼OS–PFS), TWiST
(TWiST¼PFS–TOX), and duration of TOX were calculated from
patient follow-up data. Owing to the unknown distributions of the
mean differences, non-parametric bootstrapping, a numerical
resampling method, was performed (5000 iterations) to obtain
reliable estimates of the s.e. for the clinical end points (Fine and
Gelber, 2001). P-values with 95% CI were reported on the basis of
the standard Z-statistic.
Threshold utility analysis
A threshold utility analysis assessed the Q-TWiST outcome over
seven possible combinations of TOX and REL utility values with
the TWiST utility set to 1.0 or 0.805 from the UK utility study
(Pettengell et al, 2008).
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis (PSA) was performed to address
the uncertainty of the clinical end points and the co-dependency
between utilities and the health states. This was carried out using
Monte Carlo simulations (1000 iterations), in which OS, PFS, REL,
and TOX utilities were randomly sampled from Beta-Pert distri-
butions (Vose, 2000), with the most likely and extreme values
obtained from the mean and s.e. reported in the 53-month update
(Marcus et al, 2008) and the UK utility study (Pettengell et al, 2008).
RESULTS
Q-TWiST analysis
Survival times partitioned into the three health states are shown
separately for R-CVP and CVP in Figure 1A and B, depicting the
time spent in each health state over the follow-up period.
Rituximab plus CVP-treated patients gained a mean of 15.17
months TWiST (Po0.001), and spent a mean of 11.30 months less
time in relapse (Po0.001) compared with CVP patients, without
any increase in toxicity (mean difference 0.24 months (P¼0.36;
Table 1). Using the patient-reported utility of 0.618 for REL, an
assumed utility of 0.618 for TOX, and a utility of 1.0 for TWiST,
R-CVP patients experienced a mean of 8.33 months’ longer
Q-TWiST compared with CVP (95% CI 4.51–9.25, Po0.001)
(Table 1). On the basis of PSA, the mean increase in Q-TWiST for
R-CVP compared with CVP was 7.38 (95% CI: 5.82–10.87), which
is consistent with the bootstrapped estimates.
Utility threshold analysis
Results from the threshold utility analysis show that in all cases
but one, the mean increases in Q-TWiST obtained with R-CVP vs
CVP were statistically significant (Table 2).
R-CVP CVP alone
REL
REL
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
1.00
0.75
0.50
0.25
0.00
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
1.00
0.75
0.50
0.25
0.00
TOX
TOX
Months from randomisation
TWiST
TWiST
0 1 02 03 04 05 06 07 0
Months from randomisation
0 1 02 03 04 05 06 07 0
PFS
PFS
OS
OS
Figure 1 Partitioned survival plots for (A) R-CVP and (B) CVP alone. Curves represent overall survival (OS), progression-free survival (PFS), and
treatment toxicity (TOX). Areas between the curves represent the mean time spent in the health states: TOX, time without disease symptoms or treatment
toxicity (TWiST), and time in relapse (REL), based on 53 months’ median follow-up truncated at 67 months.
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The gain function (Staquet et al, 1998; Fayers and Machin, 2000),
defined as the incremental mean differences in Q-TWiST between
R-CVP and CVP over time, is shown in Figure 2.
DISCUSSION
Comparative clinical and health outcomes
Long-term follow-up data (Marcus et al, 2008) showed statistically
significant and clinically meaningful improvement for R-CVP over
CVP in time to treatment failure and PFS, without an increase in
clinically significant toxicity. Furthermore, OS for patients treated
with R-CVP was significantly longer than for patients treated with
CVP alone (Marcus et al, 2008). Quality-adjusted time without
disease symptoms or toxicity of treatment analysis based on this
53-month update to the data shows that patients treated with
R-CVP gained more time without treatment toxicities or disease
symptoms and spent less time in relapse than did patients treated
with CVP alone. Incorporating patient-reported utilities from the
UK study in FL (Pettengell et al, 2008) confirmed the significant
improvement in quality-adjusted survival with R-CVP vs CVP
alone.
In their investigation of clinically important differences in
Q-TWiST analyses, Revicki et al (2006) suggested that differences
of 10–15% should be regarded as clinically important. A 15%
increase in Q-TWiST was obtained with R-CVP vs CVP alone
representing a clinically meaningful difference, with an 11% (mean
6.11 months) difference achieved within 12 months.
A previous Q-TWiST analysis comparing CHVP with CHVP plus
IFN-a2b in 242 patients with FL (Cole et al, 1998) showed that after
a median follow-up of 72 months, the IFN group gained a mean of
12.3 months’ PFS and 7.4 months’ OS, but experienced additional
time with grade 3 or worse toxicity, compared with the CHVP
group. In contrast, our study with 53 months’ median follow-up
revealed that R-CVP treatment resulted in a mean increase in PFS
of 15.4 months, a mean of 11.30 months’ less time spent in relapse,
with no significant increase in toxicity vs CVP alone.
Strengths and weaknesses
In the threshold utility analysis, the increase in Q-TWiST was not
statistically significant with the utility combination 0.90, 0.10 and
Table 1 Components of Q-TWiST with utility values uTOX¼0.618, uREL¼0.618, and uTWiST¼1.0
End point
a
Mean R–CVP
(months)
Mean CVP
(months)
Mean difference
(months)
95% CI for mean
difference
b (months) P-value
OS 59.68 55.56 4.11 0.50 to 6.05 0.015
PFS 39.26 23.86 15.41 8.80 to 16.07 o0.001
TOX 4.12 3.88 0.24  0.34 to 0.48 0.36
REL 20.41 31.71  11.30  13.42 to  6.21 o0.001
TWiST 35.15 19.98 15.17 8.65 to 16.06 o0.001
Q-TWiST 50.31 41.97 8.33 4.51 to 9.25 o0.001
Abbreviations: CI¼confidence interval, OS¼overall survival, PFS¼progression-free survival, Q-TWiST¼quality-adjusted time without symptoms of disease or toxicity,
REL¼disease relapse, TOX¼toxicity.
aThe estimated deterministic mean durations of the end points were restricted to 53 months median follow-up truncated at 67 months.
b95% CIs were estimated using the non-parametric bootstrap method.
Table 2 Threshold utility analysis using three-way combinations of health state utility values to estimate Q-TWiST confidence intervals
a
TWiST utility REL, TOX utilities
0.1, 0.9 0.2, 0.8 0.4, 0.6 0.5, 0.5 0.6, 0.4 0.8, 0.2 0.9, 0.1
1.0 11.96 11.00 8.98 8.00 7.00 5.01 4.02
(8.10–14.83)* (7.42–13.79)* (6.10–11.51)* (5.43–10.50)* (4.65–9.38)* (2.72–7.55)* (1.51–6.76)*
0.805 9.49 8.49 6.50 5.51 4.51 2.52 1.52
(6.48–11.83)* (5.93–10.85)* (4.46–8.58)* (3.60–7.51)* (2.67–6.54)* (0.43–4.91)
w ( 0.70–4.03)
NS
Abbreviations: Q-TWiST¼quality-adjusted time without symptoms of disease or toxicity, REL¼disease relapse, TOX¼toxicity, NS¼not statistically significant (P¼0.124).
aQ-TWiST mean differences and associated 95% confidence intervals in parentheses were estimated using the non-parametric bootstrap method. *Po0.001.
wPo0.05.
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Figure 2 Gain function of incremental mean differences in Q-TWiST
between R-CVP and CVP as a function of time (53 months’ median follow-
up truncated at 67 months). The solid line represents the incremental mean
differences in Q-TWiST over time with utilities 0.618 for TOX and REL
and 1.0 for TWiST, whereas the shaded area depicts the range of
differences in Q-TWiST, as the utility values for REL and TOX vary
between 0 and 1.
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is clinically unlikely that the QoL of FL patients who have relapsed
would be better than that of patients without symptoms or toxicity.
The bootstrap analysis incorporated uncertainty in the clinical
end points used to estimate Q-TWiST using deterministic utility
values. Probabilistic sensitivity analysis, by addressing the
relationship between OS, PFS, REL, TOX, and utilities, represents
a comprehensive sensitivity analysis to test the robustness of the
Q-TWiST outcome.
The UK utility study did not investigate patient utilities for TOX.
However, as there was no significant difference in the duration of
toxicity between the treatment arms, the Q-TWiST results were
insensitive to this utility. Finally, a median 53-month follow-up
period is relatively short given that patients with FL have a median
survival of 6–10 years (Horning, 1993). Parametric extrapolation of
the clinical data beyond this period is one approach for determining
whether R-CVP will further augment quality-adjusted survival.
CONCLUSIONS
Rituximab plus CVP-treated patients with advanced FL reached
a significant and clinically meaningful improvement within
12 months in quality-adjusted survival compared with CVP
alone.
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